Company intelligence / Profile preview
Balance Therapeutics, Inc.
Burlingame, California, United Statest-balance-therapeutics.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
Balance Therapeutics is developing therapeutics for neurological conditions, with a focus on intellectual disability and Down Syndrome. Their lead product BTD-001 has undergone clinical trials for Down Syndrome. The company's approach involves restoring the proper balance between inhibition and excitation at neuronal synapses by antagonizing excessive inhibitory circuits to improve memory and learning in conditions of intellectual disability[3][4].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Balance Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Balance Therapeutics, Inc..